메뉴 건너뛰기




Volumn 18, Issue 1, 2016, Pages

Immune response in breast cancer brain metastases and their microenvironment: The role of the PD-1/PD-L axis

Author keywords

Brain metastases; Breast cancer; Lymphocytes; PD 1; PD L

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLIAL FIBRILLARY ACIDIC PROTEIN; LAPATINIB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

EID: 84965032161     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0702-8     Document Type: Article
Times cited : (89)

References (53)
  • 1
    • 84907198355 scopus 로고    scopus 로고
    • Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
    • Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-66.
    • (2014) J Clin Oncol , vol.32 , pp. 2959-2966
    • Adams, S.1    Gray, R.J.2    Demaria, S.3    Goldstein, L.4    Perez, E.A.5    Shulman, L.N.6
  • 2
    • 84896872171 scopus 로고    scopus 로고
    • Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
    • Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611-8.
    • (2014) Ann Oncol , vol.25 , pp. 611-618
    • Dieci, M.V.1    Criscitiello, C.2    Goubar, A.3    Viale, G.4    Conte, P.5    Guarneri, V.6
  • 3
    • 84905178989 scopus 로고    scopus 로고
    • Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    • Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544-50.
    • (2014) Ann Oncol , vol.25 , pp. 1544-1550
    • Loi, S.1    Michiels, S.2    Salgado, R.3    Sirtaine, N.4    Jose, V.5    Fumagalli, D.6
  • 4
    • 84875722651 scopus 로고    scopus 로고
    • Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    • Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860-7.
    • (2013) J Clin Oncol , vol.31 , pp. 860-867
    • Loi, S.1    Sirtaine, N.2    Piette, F.3    Salgado, R.4    Viale, G.5    Eenoo, F.6
  • 5
    • 84927138902 scopus 로고    scopus 로고
    • Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
    • Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983-91.
    • (2015) J Clin Oncol , vol.33 , pp. 983-991
    • Denkert, C.1    Minckwitz, G.2    Brase, J.C.3    Sinn, B.V.4    Gade, S.5    Kronenwett, R.6
  • 6
    • 84969268378 scopus 로고    scopus 로고
    • Association of stromal tumor infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer
    • Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of stromal tumor infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2015;15:1-9.
    • (2015) JAMA Oncol , vol.15 , pp. 1-9
    • Perez, E.A.1    Ballman, K.V.2    Tenner, K.S.3    Thompson, E.A.4    Badve, S.S.5    Bailey, H.6
  • 8
    • 26244449275 scopus 로고    scopus 로고
    • Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells
    • Hudson LC, Bragg DC, Tompkins MB, Meeker RB. Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells. Brain Res. 2005;1058:148-60.
    • (2005) Brain Res , vol.1058 , pp. 148-160
    • Hudson, L.C.1    Bragg, D.C.2    Tompkins, M.B.3    Meeker, R.B.4
  • 9
    • 53949093698 scopus 로고    scopus 로고
    • Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization
    • Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis. 2008;25:799-810.
    • (2008) Clin Exp Metastasis , vol.25 , pp. 799-810
    • Fitzgerald, D.P.1    Palmieri, D.2    Hua, E.3    Hargrave, E.4    Herring, J.M.5    Qian, Y.6
  • 10
    • 77956855574 scopus 로고    scopus 로고
    • Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels
    • Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010;12:748-54.
    • (2010) Neoplasia , vol.12 , pp. 748-754
    • Lin, Q.1    Balasubramanian, K.2    Fan, D.3    Kim, S.J.4    Guo, L.5    Wang, H.6
  • 11
    • 35349024802 scopus 로고    scopus 로고
    • CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system
    • Müller M, Carter SL, Hofer MJ, Manders P, Getts DR, Getts MT, et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol. 2007;179:2774-86.
    • (2007) J Immunol , vol.179 , pp. 2774-2786
    • Müller, M.1    Carter, S.L.2    Hofer, M.J.3    Manders, P.4    Getts, D.R.5    Getts, M.T.6
  • 12
    • 77951837763 scopus 로고    scopus 로고
    • Trafficking of immune cells in the central nervous system
    • Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120:1368-79.
    • (2010) J Clin Invest , vol.120 , pp. 1368-1379
    • Wilson, E.H.1    Weninger, W.2    Hunter, C.A.3
  • 14
    • 84939633426 scopus 로고    scopus 로고
    • B7-h4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity
    • Rahbar R, Lin A, Ghazarian M, Yau HL, Paramathas S, Lang PA, et al. B7-h4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. Cancer Immunol Res. 2015;3:184-95.
    • (2015) Cancer Immunol Res , vol.3 , pp. 184-195
    • Rahbar, R.1    Lin, A.2    Ghazarian, M.3    Yau, H.L.4    Paramathas, S.5    Lang, P.A.6
  • 15
    • 84919385463 scopus 로고    scopus 로고
    • Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type
    • Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965-70.
    • (2014) Cancer Epidemiol Biomarkers Prev , vol.23 , pp. 2965-2970
    • Gatalica, Z.1    Snyder, C.2    Maney, T.3    Ghazalpour, A.4    Holterman, D.A.5    Xiao, N.6
  • 16
    • 84891654921 scopus 로고    scopus 로고
    • PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)
    • Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol. 2014;33:42-9.
    • (2014) Clin Neuropathol , vol.33 , pp. 42-49
    • Berghoff, A.S.1    Ricken, G.2    Widhalm, G.3    Rajky, O.4    Hainfellner, J.A.5    Birner, P.6
  • 17
    • 84925266488 scopus 로고    scopus 로고
    • Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases
    • Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 2015;66:289-99.
    • (2015) Histopathology , vol.66 , pp. 289-299
    • Berghoff, A.S.1    Ricken, G.2    Widhalm, G.3    Rajky, O.4    Dieckmann, K.5    Birner, P.6
  • 18
    • 84943241524 scopus 로고    scopus 로고
    • Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
    • Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;8:1064-75.
    • (2015) Neuro Oncol , vol.8 , pp. 1064-1075
    • Berghoff, A.S.1    Kiesel, B.2    Widhalm, G.3    Rajky, O.4    Ricken, G.5    Wöhrer, A.6
  • 19
    • 84950980021 scopus 로고    scopus 로고
    • Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
    • Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, et al. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015;6:40836-49.
    • (2015) Oncotarget , vol.6 , pp. 40836-40849
    • Harter, P.N.1    Bernatz, S.2    Scholz, A.3    Zeiner, P.S.4    Zinke, J.5    Kiyose, M.6
  • 20
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 21
    • 84859128199 scopus 로고    scopus 로고
    • Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    • 127ra37
    • Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.
    • (2012) Sci Transl Med , vol.4
    • Taube, J.M.1    Anders, R.A.2    Young, G.D.3    Xu, H.4    Sharma, R.5    McMiller, T.L.6
  • 22
    • 4243096258 scopus 로고    scopus 로고
    • B7-H1 expression on non small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
    • Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Aita H, Nishimura M. B7-H1 expression on non small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094-100.
    • (2004) Clin Cancer Res , vol.10 , pp. 5094-5100
    • Konishi, J.1    Yamazaki, K.2    Azuma, M.3    Kinoshita, I.4    Dosaka-Aita, H.5    Nishimura, M.6
  • 25
    • 84901620362 scopus 로고    scopus 로고
    • T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands
    • Karasar P, Esendagli G. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res Treat. 2014;145:605-14.
    • (2014) Breast Cancer Res Treat , vol.145 , pp. 605-614
    • Karasar, P.1    Esendagli, G.2
  • 26
    • 84928773222 scopus 로고    scopus 로고
    • IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
    • Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501-9.
    • (2015) Br J Cancer , vol.112 , pp. 1501-1509
    • Abiko, K.1    Matsumura, N.2    Hamanishi, J.3    Horikawa, N.4    Murakami, R.5    Yamaguchi, K.6
  • 27
    • 84959904342 scopus 로고    scopus 로고
    • Reflections on immune checkpoint inhibition in non-small cell lung cancer
    • Leventakos K, Mansfield AS. Reflections on immune checkpoint inhibition in non-small cell lung cancer. Transl Lung Cancer Res. 2014;3:411-3.
    • (2014) Transl Lung Cancer Res , vol.3 , pp. 411-413
    • Leventakos, K.1    Mansfield, A.S.2
  • 28
    • 84954429886 scopus 로고    scopus 로고
    • Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
    • Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. OncoImmunology. 2016. doi:10.1080/2162402X.2015.1057388
    • (2016) OncoImmunology
    • Berghoff, AS.1    Fuchs, E.2    Ricken, G.3    Mlecnik B.Bindea, G.4    Spanberger, T.5
  • 30
    • 84936749833 scopus 로고    scopus 로고
    • Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer
    • Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-12.
    • (2015) J Clin Oncol , vol.33 , pp. 2004-2012
    • Gettinger, S.N.1    Horn, L.2    Gandhi, L.3    Spigel, D.R.4    Antonia, S.J.5    Rizvi, N.A.6
  • 31
    • 77957664158 scopus 로고    scopus 로고
    • Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non small cell lung cancer
    • Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non small cell lung cancer. Cell Mollmmunol. 2010;7:389-95.
    • (2010) Cell Mollmmunol , vol.7 , pp. 389-395
    • Zhang, Y.1    Huang, S.2    Gong, D.3    Qin, Y.4    Shen, Q.5
  • 32
    • 0026700235 scopus 로고
    • Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
    • Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887-95.
    • (1992) EMBO J , vol.11 , pp. 3887-3895
    • Ishida, Y.1    Agata, Y.2    Shibahara, K.3    Honjo, T.4
  • 34
    • 10344220548 scopus 로고    scopus 로고
    • Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
    • Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-9.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 17174-17179
    • Thompson, R.H.1    Gillett, M.D.2    Cheville, J.C.3    Lohse, C.M.4    Dong, H.5    Webster, W.S.6
  • 35
    • 84896488675 scopus 로고    scopus 로고
    • PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients
    • Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014;63:395-406.
    • (2014) Cancer Immunol Immunother , vol.63 , pp. 395-406
    • Sun, S.1    Fei, X.2    Mao, Y.3    Wang, X.4    Garfield, D.H.5    Huang, O.6
  • 36
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD L1 antibody MPDL3280A in cancer patients
    • Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7.
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1    Soria, J.C.2    Kowanetz, M.3    Fine, G.D.4    Hamid, O.5    Gordon, M.S.6
  • 37
    • 84965058325 scopus 로고    scopus 로고
    • Modes of immune response
    • Male D, Brostoff J, Roth D, Roitt I, editors. Immunology
    • Male D. Modes of immune response. In: Male D, Brostoff J, Roth D, Roitt I, editors. Immunology. Elselvier Ltd; 2006. p. 127-249.
    • (2006) Elselvier Ltd , pp. 127-249
    • Male, D.1
  • 38
    • 84895779425 scopus 로고    scopus 로고
    • PD-L1 expression is increased in a subset of basal type breast cancer cells
    • Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014;9:e88557.
    • (2014) PLoS One , vol.9
    • Soliman, H.1    Khalil, F.2    Antonia, S.3
  • 40
    • 33846118474 scopus 로고    scopus 로고
    • Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
    • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84-8.
    • (2007) Nat Med , vol.13 , pp. 84-88
    • Parsa, A.T.1    Waldron, J.S.2    Panner, A.3    Crane, C.A.4    Parney, I.F.5    Barry, J.J.6
  • 42
    • 0038491416 scopus 로고    scopus 로고
    • Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor
    • Shin T, Kennedy G, Gorski K, Tsuchiya H, Koseki H, Azuma M, et al. Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med. 2003;198:31-8.
    • (2003) J Exp Med , vol.198 , pp. 31-38
    • Shin, T.1    Kennedy, G.2    Gorski, K.3    Tsuchiya, H.4    Koseki, H.5    Azuma, M.6
  • 43
    • 0037867039 scopus 로고    scopus 로고
    • B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism
    • Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003;197:1721-30.
    • (2003) J Exp Med , vol.197 , pp. 1721-1730
    • Liu, X.1    Gao, J.X.2    Wen, J.3    Yin, L.4    Li, O.5    Zuo, T.6
  • 44
    • 35548986304 scopus 로고    scopus 로고
    • Microglia: active sensor and versatile effector cells in the normal and pathologic brain
    • Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387-94.
    • (2007) Nat Neurosci , vol.10 , pp. 1387-1394
    • Hanisch, U.K.1    Kettenmann, H.2
  • 45
    • 77955534002 scopus 로고    scopus 로고
    • The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
    • Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160-70.
    • (2010) Cancer Cell , vol.18 , pp. 160-170
    • Park, S.1    Jiang, Z.2    Mortenson, E.D.3    Deng, L.4    Radkevich-Brown, O.5    Yang, X.6
  • 46
    • 79955570584 scopus 로고    scopus 로고
    • Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
    • Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142-7.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 7142-7147
    • Stagg, J.1    Loi, S.2    Divisekera, U.3    Ngiow, S.F.4    Duret, H.5    Yagita, H.6
  • 47
    • 78650880204 scopus 로고    scopus 로고
    • HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
    • Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 2010;12:R46.
    • (2010) Breast Cancer Res , vol.12 , pp. R46
    • Silva, L.1    Simpson, P.T.2    Smart, C.E.3    Cocciardi, S.4    Waddell, N.5    Lane, A.6
  • 48
    • 84940757399 scopus 로고    scopus 로고
    • Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases
    • Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, et al. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol. 2015;9:1241-9.
    • (2015) Neuro Oncol , vol.9 , pp. 1241-1249
    • Duchnowska, R.1    Sperinde, J.2    Chenna, A.3    Huang, W.4    Weidler, J.M.5    Winslow, J.6
  • 49
    • 84937961692 scopus 로고    scopus 로고
    • A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
    • Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 2015;75 Suppl 9:S1-09.
    • (2015) Cancer Res , vol.75 , pp. S1-09
    • Nanda, R.1    Chow, L.Q.2    Dees, E.C.3    Berger, R.4    Gupta, S.5    Geva, R.6
  • 50
    • 84965022830 scopus 로고    scopus 로고
    • Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028
    • Rugo HS, Delord J-P, Im S-A, Ott PA, Piha-Paul SA, Bedard PL, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 2016;76 Suppl 4:S5-07.
    • (2016) Cancer Res , vol.76 , pp. S5-07
    • Rugo, H.S.1    Delord, J.-P.2    Im, S.-A.3    Ott, P.A.4    Piha-Paul, S.A.5    Bedard, P.L.6
  • 51
    • 84944041240 scopus 로고    scopus 로고
    • Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastastic triple-negative breast cancer
    • Emens LA, Braiteh FS, Cassier PA, Delord J, Eder JP, Shen X, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastastic triple-negative breast cancer. Cancer Res. 2015;75 Suppl 9:PD1-6.
    • (2015) Cancer Res , vol.75 , pp. PD1-6
    • Emens, L.A.1    Braiteh, F.S.2    Cassier, P.A.3    Delord, J.4    Eder, J.P.5    Shen, X.6
  • 52
    • 85010223314 scopus 로고    scopus 로고
    • Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial
    • Dirix LY, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H-T, Hamilton EP, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76 Suppl 4:S1-04.
    • (2016) Cancer Res , vol.76 , pp. S1-04
    • Dirix, L.Y.1    Takacs, I.2    Nikolinakos, P.3    Jerusalem, G.4    Arkenau, H.-T.5    Hamilton, E.P.6
  • 53
    • 84902590227 scopus 로고    scopus 로고
    • Immune checkpoints: A therapeutic target in triple negative breast cancer
    • Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology. 2014;3:e28325.
    • (2014) Oncoimmunology , vol.3 , pp. e28325
    • Chawla, A.1    Philips, A.V.2    Alatrash, G.3    Mittendorf, E.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.